Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Shanghai Henlius Biotech Inc (Henlius), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co Ltd, is a biopharmaceutical company that develops medicine for oncology, autoimmune and ophthalmic diseases. It offers HANLIKANG, a rituximab injection, which treats non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HERCESSI, trastuzumab for injection for breast, metastatic breast and metastatic gastric cancer; Handayuan, Adalimumab injection, which targets rheumatoid arthritis, Ankylosing spondylitis, Psoriasis, Uveitis, Crohn's disease and Children Crohn's disease; Hanbeitai Bevacizumab injection, which treats metastatic Colorectal, recurrent glioblastoma, epithelial ovarian cancer and others and Hans-Shape, Slulizumab injection, for microsatellite high instability (MSI-H) solid tumors, squamous non-small cell lung cancer (sqNSCLC). Henlius is headquartered in Shanghai, China.
Headquarters
China
Address
11th Floor, B8 Building, No. 188 Yizhou Road, Shanghai, 200233
Website
www.henlius.com
Telephone
86 21 33395800
No of Employees
3,762
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
2696 (HKG)
Revenue (2024)
$927.6M
16.5%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
0.8%
(2024 vs 2023)
Market Cap*
$4.4B
Net Profit Margin (2024)
XYZ
-13.4%
(2024 vs 2023)
* As of and is in US$
Shanghai Henlius Biotech Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Rituximab Injection | Hans- Shape |
| Trastuzumab for Injection | Hanbeitai |
| Adalimumab Injection | Handayuan |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In April, the company received approval from the National Medical Products Administration for two new indications under non-Hodgkin's lymphoma of HANLIKANG (rituximab). |
| 2026 | Contracts/Agreements | In February, Henlius Biotech signed an exclusive licensing agreement with Abbott to allow the company to commercialize its innovative anti-PD-1 monoclonal antibody H-drug, Hanszal. |
| 2026 | Regulatory Approval | In January, the company received approval from the China National Medical Products Administration for a clinical trial of HLX43, a programmed death-ligand 1 (PD-L1) targeting antibody-drug conjugate, in combination with the company's anti-PD-1 monoclonal antibody HANSIZHUANG (serplulimab) for the treatment of advanced solid tumors. |
Competitor Comparison
| Key Parameters | Shanghai Henlius Biotech Inc | Jinyao Pharmaceutical Co Ltd | Sihuan Pharmaceutical Holdings Group Ltd | BrightGene Bio-Medical Technology Co Ltd | China Pharma Holdings Inc |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Shanghai | Tianjin | Beijing | Suzhou | Haikou |
| State/Province | Shanghai | Tianjin | Beijing | Jiangsu | Hainan |
| No. of Employees | 3,762 | 2,884 | 2,843 | 1,196 | 215 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jun Zhu | Director; Chief Executive Officer | Executive Board | 2023 | 46 |
| Yingbo Mao | Chief Financial Officer; Vice President | Senior Management | 2024 | 47 |
| Simon Hsu | Chief Technology Officer; Senior Vice President | Senior Management | - | - |
| Wei Huang | President | Senior Management | 2023 | 57 |
| Feng Ye | Chief Quality Officer; Vice President | Senior Management | 2024 | 57 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer